
John D Lich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12156101/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Medicinal Chemistry Letters, 2019, 10, 857-862.	2.8	52
2	Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase. Journal of Medicinal Chemistry, 2019, 62, 5096-5110.	6.4	42
3	RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell, 2018, 34, 757-774.e7.	16.8	170
4	Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry, 2017, 60, 1247-1261.	6.4	353
5	Identification of an antibodyâ€based immunoassay for measuring direct target binding of <scp>RIPK</scp> 1 inhibitors in cells and tissues. Pharmacology Research and Perspectives, 2017, 5, e00377.	2.4	8
6	Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Medicinal Chemistry Letters, 2013, 4, 1238-1243.	2.8	117
7	Characterization of NLRP12 during the In Vivo Host Immune Response to Klebsiella pneumoniae and Mycobacterium tuberculosis. PLoS ONE, 2013, 8, e60842.	2.5	50
8	NLRP12 Suppresses Colon Inflammation and Tumorigenesis through the Negative Regulation of Noncanonical NF-κB Signaling. Immunity, 2012, 36, 742-754.	14.3	421
9	Characterization of NLRP12 during the Development of Allergic Airway Disease in Mice. PLoS ONE, 2012, 7, e30612.	2.5	35
10	Cutting Edge: NLRP12 Controls Dendritic and Myeloid Cell Migration To Affect Contact Hypersensitivity. Journal of Immunology, 2010, 185, 4515-4519.	0.8	134
11	NLRX1 is a regulator of mitochondrial antiviral immunity. Nature, 2008, 451, 573-577.	27.8	501
12	ATP Binding by Monarch-1/NLRP12 Is Critical for Its Inhibitory Function. Molecular and Cellular Biology, 2008, 28, 1841-1850.	2.3	96
13	Heat Shock Protein 90 Associates with Monarch-1 and Regulates Its Ability to Promote Degradation of NF-κB-Inducing Kinase. Journal of Immunology, 2007, 179, 6291-6296.	0.8	62
14	Cutting Edge: Monarch-1 Suppresses Non-Canonical NF-κB Activation and p52-Dependent Chemokine Expression in Monocytes. Journal of Immunology, 2007, 178, 1256-1260.	0.8	180
15	CATERPILLER (NLR) Family Members as Positive and Negative Regulators of Inflammatory Responses. Proceedings of the American Thoracic Society, 2007, 4, 263-266.	3.5	18
16	Monarch-1/PYPAF7 and other CATERPILLER (CLR, NOD, NLR) proteins with negative regulatory functions. Microbes and Infection, 2007, 9, 672-676.	1.9	44
17	Cryopyrin: In from the Cold. Immunity, 2006, 24, 241-243.	14.3	18
18	Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnology, 2006, 6, 7.	3.3	107

Јони D Lich

#	Article	IF	CITATIONS
19	Cutting Edge: ASC Mediates the Induction of Multiple Cytokines by <i>Porphyromonas gingivalis</i> via Caspase-1-Dependent and -Independent Pathways. Journal of Immunology, 2006, 177, 4252-4256.	0.8	73
20	The CATERPILLER Protein Monarch-1 Is an Antagonist of Toll-like Receptor-, Tumor Necrosis Factor α-, and Mycobacterium tuberculosis-induced Pro-inflammatory Signals. Journal of Biological Chemistry, 2005, 280, 39914-39924.	3.4	191
21	Editing of an Immunodominant Epitope of Glutamate Decarboxylase by HLA-DM. Journal of Immunology, 2003, 171, 853-859.	0.8	41
22	Cutting Edge: Editing of Recycling Class II:Peptide Complexes by HLA-DM. Journal of Immunology, 2001, 167, 632-635.	0.8	49
23	Cytoplasmic Processing Is a Prerequisite for Presentation of an Endogenous Antigen by Major Histocompatibility Complex Class II Proteins. Journal of Experimental Medicine, 2000, 191, 1513-1524.	8.5	136